Aligos Therapeutics, Inc.ALGSEarnings & Financial Report
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
Revenue
$606.0K
Gross Profit
N/A
Operating Profit
$-20.6M
Net Profit
$-82.2M
Gross Margin
N/A
Operating Margin
-3393.2%
Net Margin
-13556.1%
YoY Growth
-9.8%
EPS
$-13.10
Aligos Therapeutics, Inc. Q4 FY2024 Financial Summary
Aligos Therapeutics, Inc. reported revenue of $606.0K (down 9.8% YoY) for Q4 FY2024, with a net profit of $-82.2M (down 194.5% YoY) (-13556.1% margin).
Key Financial Metrics
| Total Revenue | $606.0K |
|---|---|
| Net Profit | $-82.2M |
| Gross Margin | N/A |
| Operating Margin | -3393.2% |
| Report Period | Q4 FY2024 |
Aligos Therapeutics, Inc. Annual Revenue by Year
Aligos Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $2.2M |
| 2024 | $3.6M |
| 2023 | $6.2M |
Aligos Therapeutics, Inc. Quarterly Revenue & Net Profit History
Aligos Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $169.0K | -72.1% | N/A | N/A |
| Q3 FY2025 | $741.0K | -40.7% | $-31.5M | -4256.0% |
| Q2 FY2025 | $965.0K | -9.0% | $-15.9M | -1643.8% |
| Q1 FY2025 | $311.0K | -55.2% | $43.1M | 13854.7% |
| Q4 FY2024 | $606.0K | -9.8% | $-82.2M | -13556.1% |
| Q3 FY2024 | $1.3M | +15.2% | $-19.3M | -1540.7% |
| Q2 FY2024 | $1.1M | -75.3% | $5.1M | 477.0% |
| Q1 FY2024 | $694.0K | +395.7% | $-34.9M | -5023.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $694000 | $1.1M | $1.3M | $606000 | $311000 | $965000 | $741000 | $169000 |
| YoY Growth | 395.7% | -75.3% | 15.2% | -9.8% | -55.2% | -9.0% | -40.7% | -72.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $127.9M | $108.8M | $88.4M | $70.1M | $150.7M | $134.7M | $109.8M | $88.5M |
| Liabilities | $68.1M | $41.6M | $38.3M | $99.1M | $34.3M | $32.8M | $37.9M | $35.0M |
| Equity | $59.8M | $67.2M | $50.1M | $-29.0M | $116.4M | $101.9M | $71.8M | $53.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-22.7M | $-19.5M | $-20.1M | $-18.4M | $-20.9M | $-15.5M | $-24.3M | $-82.5M |